Table 2

Seroprotection and seroconversion rates of influenza A (H1N1) 2009 vaccine in ARD patients and controls

Seroprotection rate (titre ≥1/40)
Before immunisationAfter immunisation
N% (95% CI)Seroconversion rate
ARD166810.3 (8.8 to 11.8)68.5 (66.3 to 70.7)*63.4 (61.1 to 65.7)*
SLE5728.9 (6.6 to 11.2)64.9 (61.0 to 68.8)*60.5 (56.5 to 64.5)*
RA34310.8 (7.5 to 14.1)60.1 (54.9 to 65.3)*53.4 (48.1 to 58.7)*
PsA1017.9 (2.6 to 13.2)65.3 (56.0 to 74.6)*57.4 (47.8 to 67.0)*
AS1528.6 (4.1 to 13.1)73.7 (66.7 to 80.7)*69.8 (62.5 to 77.1)
BD857.1 (1.6 to 12.6)71.8 (62.2 to 81.4)*69.4 (59.6 to 79.2)
DM458.9 (0.6 to 17.2)68.9 (55.4 to 82.4)*66.7 (52.9 to 80.5)
SSc12718.1 (11.4 to 24.8)81.1 (74.3 to 87.9)73.2 (65.5 to 80.9)
MCTD6910.1 (3.0 to 17.2)75.4 (65.2 to 85.6)68.1 (57.1 to 79.1)
PAPS545.6 (−0.5 to 11.7)79.6 (68.8 to 90.3)77.8 (66.7 to 88.9)
pSS3611.1 (0.8 to 21.4)83.3 (71.1 to 95.5)77.8 (64.2 to 91.4)
TA3013.3 (1.1 to 25.4)90 (79.3 to 100.7)86.7 (74.5 to 98.8)
PM2821.4 (6.2 to 36.6)82.1 (67.9 to 96.3)82.1 (67.8 to 96.3)
WG2619.2 (4.1 to 34.3)69.2 (51.4 to 86.9)65.4 (47.1 to 83.7)
Control23411.5 (7.4 to 15.6)82.9 (78.1 to 87.7)76.9 (71.5 to 82.3)
  • Data are expressed in % (95% CI).

  • * p<0.05. Comparison between patients and controls

  • ARD, autoimmune rheumatic diseases; AS, ankylosing spondylitis; BD, Behçet's disease; DM, dermatomyositis; MCTD, mixed connective tissue disease; PAPS, primary antiphospholipid syndrome; PM, polymyositis; PsA, psoriatic arthritis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; TA, Takayasu's arteritis; WG, Wegener's granulomatosis.